You are viewing the site in preview mode

Skip to content

Advertisement

  • Poster presentation
  • Open Access

HLA-G-specific microRNAs a novel approach for targeting tumors

  • 1,
  • 2,
  • 2,
  • 3,
  • 3,
  • 1 and
  • 1
Journal for ImmunoTherapy of Cancer20131 (Suppl 1) :P174

https://doi.org/10.1186/2051-1426-1-S1-P174

  • Published:

Keywords

  • Renal Cell Carcinoma
  • Prognostic Marker
  • Surface Expression
  • Adaptive Immune Response
  • Protein Expression Level

Immune inhibitory molecules on immune cells as well as on tumor cells appear to play a key role in modulating the immunogenicity of tumors and the efficacy of immunotherapies. One mediator is represented by the non-classical HLA-G antigen, which is often overexpressed in human tumors when compared to corresponding normal tissues thereby inhibiting both innate as well as adaptive immune responses. Since discordant HLA-G transcript and protein expression levels were often found in tumors of distinct origin posttranscriptional control mechanisms have been recently suggested. Indeed, different HLA-G-specific miRs have been identified, which were able to downregulate HLA-G surface expression. The miR-mediated inhibition of HLA-G enhanced the NK cell recognition. These miRs were also differentially expressed in renal cell carcinoma (RCC) versus normal kidney epithelium. Immunohistochemical analysis demonstrated of a high frequency HLA-G expression in RCC lesions, which was associated with disease progression and inversely correlated with the expression of HLA-G-specific miRs. These data postulate that HLA-G-specific miRs might be used as prognostic markers as well as potential therapeutics for targeting HLA-G expressing RCC.

Authors’ Affiliations

(1)
Martin Luther University Halle-Wittenberg, Institute of Medical Immunology, Halle, Germany
(2)
University of Erlangen, Institute of Pathology, Erlangen, Germany
(3)
Martin Luther University Halle-Wittenberg, Institute of Molecular Medicine, Halle, Germany

Copyright

© Jasinski-Bergner et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement